OPEN END TURBO PUT WARRANT - ELI LILLY & CO | Market Closed - Deutsche Boerse AG 18:37:05 27/06/2024 BST | ||
| 1.23 EUR | -26.79% |
|
| Current month | -86.96% | ||
| 1 month | -87.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 1.23 | -26.79% |
| 26/06/24 | 1.68 | +22.63% |
| 25/06/24 | 1.37 | -23.89% |
| 24/06/24 | 1.8 | -38.98% |
| 21/06/24 | 2.95 | +41.15% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 06:37 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| WKN | UL8JSH |
| ISIN | DE000UL8JSH1 |
| Date issued | 16/10/2023 |
| Strike | 916.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 29.16 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 35.04 € |
|---|---|
| Lowest since issue | 0.7 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
909
USD
Average target price
860.5
USD
Spread / Average Target
-5.33%
- Stock Market
- Certificates
- Certificat
